SCHEMBL5128968

SCHEMBL5128968

Cc1sc2nc(-c3ccccn3)nc(NCc3ccc4c(c3)OCO4)c2c1C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
HIF1A Q16665 3/20 0.44
PDE5A O76074 3/20 0.44
MAPT P10636 3/20 0.44
NPSR1 Q6W5P4 1/20 0.44
USP1 O94782 1/20 0.43
WDR48 Q8TAF3 1/20 0.43
MAPK1 P28482 3/20 0.43
LMNA P02545 2/20 0.43
TSHR P16473 2/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CREBBP Q92793 1/20 0.43
TGFBR1 P36897 1/20 0.42
TGFBR2 P37173 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
USP2 O75604 1/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118041 0.94 ALDH1A1 (0.48) ALDH1A1HIF1APDE5AMAPTLMNA
SCHEMBL5127817 0.91 METAP1 (0.44) ALDH1A1L3MBTL1HIF1APDE5AMAPT
SCHEMBL5124656 0.91 ALDH1A1 (0.43) ALDH1A1L3MBTL1HIF1APDE5AMAPT
SCHEMBL5120075 0.88 MAPT (0.45) ALDH1A1PDE5AMAPTNPSR1LMNA
SCHEMBL5117152 0.86 HIF1A (0.43) ALDH1A1HIF1APDE5AMAPTMEN1
SCHEMBL7617363 0.86 ALDH1A1 (0.46) ALDH1A1L3MBTL1HIF1AMAPTMAPK1
SCHEMBL5119670 0.85 HIF1A (0.46) ALDH1A1L3MBTL1HIF1APDE5AMAPT
SCHEMBL5119043 0.84 USP1 (0.50) ALDH1A1L3MBTL1HIF1APDE5AMAPT
SCHEMBL5123656 0.84 PRKCI (0.58) ALDH1A1MAPTNPSR1MAPK1LMNA
SCHEMBL5778467 0.84 MEN1 (0.52) ALDH1A1L3MBTL1PDE5AMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed
EP-0920431-A1 THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 1999-06-09 EP disclosed
WO-1998006722-A1 THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 1998-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ALDH1A1 1055/4885L3MBTL1 2278/4885HIF1A 2022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.